Alaunos Therapeutics(US:TCRT)2025-11-14 21:15Financial Performance - For the nine months ended September 30, 2025, the company reported a net loss of $3.3 million, with an accumulated deficit of approximately $923.7 million since its inception in 2003[110]. - The company has not generated any product revenue and has only reported nominal royalty revenue of $2,000 for the nine months ended September 30, 2025, a decrease of 67% from $6,000 in 2024[127]. - The accumulated deficit as of September 30, 2025, was approximately $923.7 million, indicating ongoing losses since inception in 2003[133]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $2.5 million, a decrease from $4.38 million for the same period in 2024[145]. Expenses - Research and development expenses for the three months ended September 30, 2025, increased by 228% to $469,000 compared to $143,000 for the same period in 2024, primarily due to increased stock-based compensation and consulting fees[122]. - General and administrative expenses for the three months ended September 30, 2025, decreased by 29% to $1,007,000 from $718,000 in the same period in 2024, mainly due to reduced salary and operational costs[123]. - General and administrative expenses for the nine months ended September 30, 2025, decreased by $1.30 million to $2.318 million compared to $3.615 million in 2024, reflecting cost-cutting measures[129]. Cash and Liquidity - As of September 30, 2025, the company had approximately $1.9 million in cash and cash equivalents, with a monthly cash burn rate of $0.28 million, expected to fund operations into the first quarter of 2026[132][134]. - Working capital as of September 30, 2025, was $1.8 million, consisting of $2.7 million in current assets and $0.9 million in current liabilities[133]. - Net cash flows from financing activities for the nine months ended September 30, 2025, were $3.26 million, attributed to proceeds from the issuance of common stock and preferred stock[147]. - The company anticipates needing to raise additional capital to continue operations beyond the forecasted runway, with no committed sources of additional capital currently available[134]. - The forecast of cash resources involves risks and uncertainties, and actual expenses may vary materially from planned estimates[135]. Strategic Initiatives - The company is exploring strategic alternatives, including acquisitions and partnerships, to maximize stockholder value amid ongoing operational challenges[116]. - The company is advancing a preclinical small molecule oral obesity program, with initial data from ongoing studies expected by the fourth quarter of 2025[113]. - The company has engaged a contract development and manufacturing organization to synthesize active pharmaceutical ingredients for its product candidates as part of its obesity program[112]. Other Income - Other income for the three months ended September 30, 2025, increased by 22% to $28,000 compared to $23,000 in the same period in 2024, primarily due to interest earned on cash reserves[124]. Preferred Stock - Cumulative preferred dividends for Series A-1 and A-2 totaled $39 thousand and $23 thousand, respectively, as of September 30, 2025[144]. - The company raised $0.5 million from the sale of 500 shares of Series A-1 Convertible Preferred Stock at $1,000 per share in April 2025[136]. - In June 2025, the company entered into a Securities Purchase Agreement, selling 338,725 shares of common stock at $3.36 per share, resulting in net proceeds of $1.911 million[139].